ストックスクリーナーアプリを入手
51.74
5.91%
-3.25
プレマーケット:
51.35
-0.39
-0.75%
前日終値:
$54.99
開ける：
$54.61
24時間の取引高:
816.77K
Relative Volume:
0.67
時価総額：
$2.12B
収益：
$147.17M
当期純損益:
$-408.35M
株価収益率:
-4.6284
EPS:
-11.1787
ネットキャッシュフロー:
$-299.92M
1週間 パフォーマンス:
+10.32%
1か月 パフォーマンス:
+3.01%
6か月 パフォーマンス:
-16.14%
1年 パフォーマンス:
+132.54%
1日の値動き範囲:
$51.24
$55.12
1週間の範囲:
$47.90
$55.36
52週間の値動き範囲:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
51.74 | 2.12B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
488.19 | 181.35B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
192.12 | 135.96B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
577.44 | 45.86B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.84 | 32.45B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.09 | 29.83B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | TD Cowen | Hold → Buy |
| 2026-02-19 | 開始されました | TD Cowen | Hold |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-11-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-10-17 | 開始されました | Guggenheim | Neutral |
すべてを表示
Grail Inc (GRAL) 最新ニュース
[144] GRAIL, Inc. SEC Filing - Stock Titan
Director Ragusa reports multiple GRAL stock sales and RSU vesting (GRAL) - Stock Titan
GRAIL (NASDAQ:GRAL) Shares Down 4%Here's Why - MarketBeat
Why Grail’s Stock Keeps Sinking Despite New Deals - TipRanks
Here’s what analysts are saying about Grail Inc. (GRAL) - MSN
GRAIL, Inc. Opens with 5.11% Gain, Outperforming S&P 500's 1.01% Rise - Markets Mojo
Is GRAIL (GRAL) Turning Superpower Partnership Into a Scalable Edge in Preventative Oncology? - simplywall.st
Price-Driven Insight from (GRAL) for Rule-Based Strategy - Stock Traders Daily
GRAL SEC FilingsGrail Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRAIL (GRAL) Price Target Decreased by 10.52% to 85.07 - MSN
GRAL Investors Invited to Join Fraud Investigation - nationaltoday.com
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
GRAL Technical Analysis & Stock Price Forecast - Intellectia AI
Grail (GRAL) rated buy by Guggenheim on Galleri potential - MSN
GRAIL, Inc. (GRAL) stock price, news, quote and history - Yahoo Finance Singapore
GRAIL, Inc. (GRAL) interactive stock chart - Yahoo Finance Singapore
GRAIL, Inc. (GRAL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Superpower partners with GRAIL to offer multi-cancer blood test By Investing.com - au.investing.com
Grail partnering with Superpower to offer Galleri cancer early detection test - MSN
Superpower Announces Strategic Partnership With GRAIL For Multi-Cancer Early Detection Test - tradingview.com
Superpower partners with GRAIL to offer multi-cancer blood test - Investing.com
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection - ChartMill
Why Grail’s Stock Is Surging Again Today - TipRanks
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - PR Newswire
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
Adobe Illustrator just got the holy grail of illustration tools - Fast Company
Grail (GRAL) Rated Buy by Guggenheim on Galleri Potential - Insider Monkey
GRAIL (GRAL): Guggenheim Lowers Price Target to $75, Maintains B - GuruFocus
UBS (AMUB) offers 15.30% autocallable notes linked to GRAIL (GRAL) - Stock Titan
GRAIL, Inc. Stock Hits Day Low of $47.55 Amid Price Pressure - Markets Mojo
Guggenheim Cuts GRAIL Price Target to $75 - nationaltoday.com
GRAIL (NASDAQ:GRAL) Given New $75.00 Price Target at Guggenheim - MarketBeat
Grail price target lowered to $75 from $130 at Guggenheim - TipRanks
JPMorgan Chase Boosts Stake in Cancer Screening Firm GRAIL - National Today
JPMorgan Chase & Co. Raises Stake in GRAIL, Inc. $GRAL - marketbeat.com
GRAIL (NASDAQ:GRAL) Stock Price Down 7.5%Time to Sell? - MarketBeat
Why GRAIL Inc Shares Keep Sliding This Week - TipRanks
Vanguard disaggregates holdings; GRAIL now shows 0% ownership (GRAL) - stocktitan.net
Here's Why Grail Stock Soared Higher This Week - Yahoo Finance
Here's Why Grail Stock Soared Higher This Week - The Motley Fool
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went ... - caledonianrecord.com
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures - AD HOC NEWS
Why Grail Stock Is Surging Back With Force - TipRanks
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures - AD HOC NEWS
Illumina Inc. stock faces ongoing challenges from Grail divestiture and genomics market pressures - AD HOC NEWS
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWS
(GRAL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path - Investing.com Canada
One Fin Capital Exits GRAIL Position, Sells 380,000 SharesNews and Statistics - IndexBox
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path By Investing.com - Investing.com South Africa
Grail Inc (GRAL) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
1.47%
大文字化:
|
ボリューム (24 時間):